2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text (Rapid PDF) All Versions of this Article: ASN.2006040331v1 17/9/2599    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Menon, V. Articles by Sarnak, M. J. Search for Related Content PubMed PubMed Citation Articles by Menon, V. Articles by Sarnak, M. J.

Received April 10, 2006
Accepted on June 29, 2006

CLINICAL SCIENCE: Epidemiology and Outcomes

Adiponectin and Mortality in Patients with Chronic Kidney Disease

Vandana Menon ^*1, Lijun Li ^*, Xuelei Wang , Tom Greene , Vaidyanathapuram Balakrishnan ^*, Magdalena Madero ^*, Arema A. Pereira ^*, Gerald J. Beck , John W. Kusek , Allan J. Collins , Andrew S. Levey ^*, and Mark J. Sarnak ^*

*Department of Medicine, Division of Nephrology, Tufts-New England Medical Center, Boston, Massachusetts; Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio; National Institutes of Health, Bethesda, Maryland; and Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota

¹ To whom correspondence should be addressed. E-mail: vmenon{at}tufts-nemc.org.

	Abstract

Adiponectin is presumed to possess antiatherogenic and cardioprotective properties. Limited data exist on the relationship between adiponectin and mortality in the earlier stages of chronic kidney disease. The Modification of Diet in Renal Disease study was a randomized, controlled trial that was conducted between 1989 and 1993. Adiponectin was measured in frozen samples that were obtained at baseline (N = 820). Survival status and cause of death, up to December 31, 2000, were obtained from the National Death Index. Multivariable Cox models were used to examine the relationship of adiponectin with all-cause and cardiovascular mortality. Mean ± SD age was 52 ± 12 yr, and mean ± SD glomerular filtration rate (GFR) rate was 33 ± 12 ml/min per 1.73 m². Eighty-five percent of participants were white, and 60% were male. Mean ± SD adiponectin was 12.8 ± 8.0 µg/ml. Triglycerides, insulin resistance, glucose, body mass index, GFR, C-reactive protein, and albumin were inversely related and proteinuria and HDL cholesterol were directly related to adiponectin. During the 10-year follow-up period, 201 (25%) participants died of any cause, and 122 (15%) from cardiovascular disease. In multivariable adjusted Cox models, a 1-µg/ml increase in adiponectin was associated with a 3% (hazard ratio 1.03; 95% confidence interval 1.01 to 1.05; P = 0.02) increased risk for all-cause and 6% (hazard ratio 1.06; 95% confidence interval 1.03 to 1.09; P < 0.001) increased risk for cardiovascular mortality. High, rather than low, adiponectin is associated with increased mortality in this cohort of patients with chronic kidney disease stages 3 to 4. Further studies are necessary to confirm this association and to elucidate the underlying mechanisms.

This article has been cited by other articles:

				C. Zoccali and F. Mallamaci Obesity, diabetes, adiponectin and the kidney: a podocyte affair Nephrol. Dial. Transplant., December 1, 2008; 23(12): 3767 - 3770. [Full Text] [PDF]

				J. Axelsson The emerging biology of adipose tissue in chronic kidney disease: from fat to facts Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3041 - 3046. [Full Text] [PDF]

				N. Sattar and S. M. Nelson Adiponectin, Diabetes, and Coronary Heart Disease in Older Persons: Unraveling the Paradox J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3299 - 3301. [Full Text] [PDF]

				J. R. Kizer, J. I. Barzilay, L. H. Kuller, and J. S. Gottdiener Adiponectin and Risk of Coronary Heart Disease in Older Men and Women J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3357 - 3364. [Abstract] [Full Text] [PDF]

				G. Maiolino, M. Cesari, D. Sticchi, M. Zanchetta, L. Pedon, K. Antezza, A. C. Pessina, and G. P. Rossi Plasma Adiponectin for Prediction of Cardiovascular Events and Mortality in High-Risk Patients J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3333 - 3340. [Abstract] [Full Text] [PDF]

				M. Rao, L. Li, H. Tighiouart, B. L. Jaber, B. J. G. Pereira, V. S. Balakrishnan, and the HEMO Study Group Plasma adiponectin levels and clinical outcomes among haemodialysis patients Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2619 - 2628. [Abstract] [Full Text] [PDF]

				M. Saraheimo, C. Forsblom, L. Thorn, J. Waden, M. Rosengard-Barlund, O. Heikkila, K. Hietala, D. Gordin, J. Frystyk, A. Flyvbjerg, et al. Serum Adiponectin and Progression of Diabetic Nephropathy in Patients With Type 1 Diabetes Diabetes Care, June 1, 2008; 31(6): 1165 - 1169. [Abstract] [Full Text] [PDF]

				T. A. Ikizler, P. Stenvinkel, and B. Lindholm Resolved: Being Fat Is Good for Dialysis Patients: The Godzilla Effect: Pro J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1059 - 1064. [Abstract] [Full Text] [PDF]

				S. P. Marso, S. K. Mehta, A. Frutkin, J. A. House, J. R. McCrary, and K. R. Kulkarni Low Adiponectin Levels Are Associated With Atherogenic Dyslipidemia and Lipid-Rich Plaque in Nondiabetic Coronary Arteries Diabetes Care, May 1, 2008; 31(5): 989 - 994. [Abstract] [Full Text] [PDF]

				J. M. Dekker, T. Funahashi, G. Nijpels, S. Pilz, C. D. A. Stehouwer, M. B. Snijder, L. M. Bouter, Y. Matsuzawa, I. Shimomura, and R. J. Heine Prognostic Value of Adiponectin for Cardiovascular Disease and Mortality J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1489 - 1496. [Abstract] [Full Text] [PDF]

				R. Schnabel, C. M. Messow, E. Lubos, C. Espinola-Klein, H. J. Rupprecht, C. Bickel, C. Sinning, S. Tzikas, T. Keller, S. Genth-Zotz, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study Eur. Heart J., March 1, 2008; 29(5): 649 - 657. [Abstract] [Full Text] [PDF]

				P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimburger, and Z. Massy Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle? Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 505 - 521. [Abstract] [Full Text] [PDF]

				J. J. Carrero, O. Heimburger, P. Stenvinkel, and B. Lindholm Reply to A Molfino et al Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1551 - 1553. [Full Text] [PDF]

				S. G. Wannamethee, P. H. Whincup, L. Lennon, and N. Sattar Circulating Adiponectin Levels and Mortality in Elderly Men With and Without Cardiovascular Disease and Heart Failure Arch Intern Med, July 23, 2007; 167(14): 1510 - 1517. [Abstract] [Full Text] [PDF]

				R. Barazzoni, A. Bernardi, F. Biasia, A. Semolic, A. Bosutti, M. Mucci, F. Dore, M. Zanetti, and G. Guarnieri Low fat adiponectin expression is associated with oxidative stress in nondiabetic humans with chronic kidney disease--impact on plasma adiponectin concentration Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R47 - R54. [Abstract] [Full Text] [PDF]

				I. M. Wahba and R. H. Mak Obesity and Obesity-Initiated Metabolic Syndrome: Mechanistic Links to Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 550 - 562. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673